The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medtronic's revenues will contract -1.0% and EPS will expand 7.6%.
The average estimate for revenue is $4.01 billion. On the bottom line, the average EPS estimate is $0.85.
Last quarter, Medtronic reported revenue of $4.30 billion. GAAP reported sales were 3.1% higher than the prior-year quarter's $4.17 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.99. GAAP EPS of $0.95 for Q4 were 34% higher than the prior-year quarter's $0.71 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.6%, 50 basis points worse than the prior-year quarter. Operating margin was 29.5%, 40 basis points worse than the prior-year quarter. Net margin was 23.1%, 450 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $16.46 billion. The average EPS estimate is $3.66.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,733 members out of 1,825 rating the stock outperform, and 92 members rating it underperform. Among 495 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 478 give Medtronic a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medtronic is outperform, with an average price target of $42.90.
Can your retirement portfolio provide you with enough income to last? You'll need more than Medtronic. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Medtronic to My Watchlist.